Trillium Asset Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-43,760
Closed -$4.62M 235
2025
Q4
$4.62M Sell
43,760
-8,409
-16% -$675K 0.14% 122
2025
Q3
$2.85M Sell
52,169
-846
-2% -$42.3K 0.08% 145
2025
Q2
$2.82M Sell
53,015
-336
-0.6% -$17.1K 0.08% 143
2025
Q1
$2.31M Sell
53,351
-2,820
-5% -$143K 0.07% 149
2024
Q4
$3.16M Sell
56,171
-2,450
-4% -$152K 0.08% 150
2024
Q3
$3.99M Buy
+58,621
New +$3.31M 0.1% 150
2022
Q1
Sell
-53,021
Closed -$4.13M 243
2021
Q4
$4.13M Buy
53,021
+1,066
+2% +$94.1K 0.1% 146
2021
Q3
$4.96M Buy
51,955
+2,530
+5% +$267K 0.13% 126
2021
Q2
$6.14M Buy
+49,425
New +$5.9M 0.17% 118

Other funds holding EXAS

Trillium Asset Management's EXAS Position: Q1 2026 in Review

Trillium Asset Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 43,760 shares — an estimated $4.62M sold.

Trillium Asset Management first reported a position in EXAS in Q2 2021 and held it in 9 quarters. The position peaked at $6.14M in Q2 2021. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Trillium Asset Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Trillium Asset Management sold 43,760 Exact Sciences shares in Q1 2026, an estimated $4.62M.
  • Trillium Asset Management first reported a position in Exact Sciences in Q2 2021 and held it in 9 quarters.
  • Trillium Asset Management's Exact Sciences position peaked at $6.14M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Trillium Asset Management's 13F filing for Q1 2026, filed 11 May 2026.